NAMSA Acquires CRI: Expanding Clinical Research and Reach Across Europe

NAMSA, a leading MedTech Contract Research Organization (CRO) based in Toledo, Ohio, has recently announced its acquisition of CRI - The Clinical Research Institute, a full-service CRO located in Germany. This strategic move aims to enhance NAMSA's services in Germany and expand its CRO offerings throughout Europe.

CRI, founded in 2011, has been dedicated to providing complete clinical research solutions to the European MedTech market. With a team of experienced researchers and cutting-edge data solutions, CRI supports its customers across the clinical research continuum.

"We are delighted to welcome CRI to NAMSA," said Dr. Christophe Berthoux, CEO of NAMSA. "This acquisition strengthens our presence in Germany and allows us to offer expanded services to our clients across all markets in Europe. We are excited about the new opportunities this brings, as we continue our mission of saving patients' lives."

NAMSA's clinical research services include clinical study management, post-market studies, biostatistics and data management, safety reporting, and imaging core lab services. With a team of experts experienced in various technologies, therapies, indications, and geographies, NAMSA can lead clients through all phases of clinical research.

Both NAMSA and CRI are dedicated to delivering unparalleled service and resources to the medical device and diagnostic sectors. The acquisition will enable the two organizations to establish themselves as the foremost MedTech CRO for cardiovascular research services globally.

Elisabeth Freund, Founder of CRI, expressed her confidence in the abilities of the teams to leverage their expertise and continue delivering superior results to global clients.

The financial details of the transaction remain undisclosed. However, it is worth noting that NAMSA is an ARCHIMED company, acquired by the healthcare-focused global private equity firm in 2020. This acquisition marks the 8th acquisition of NAMSA since becoming an ARCHIMED company.

About NAMSA:

NAMSA has been helping medical device sponsors improve healthcare since 1967. As the world's leading MedTech Contract Research Organization, NAMSA offers global end-to-end development services. With its global regulatory expertise and deep therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development and providing proven solutions to move clients' products through the development lifecycle efficiently and cost-effectively. NAMSA offers a range of services, including medical device testing, regulatory and quality consulting, and clinical research services.

About CRI:

CRI - The Clinical Research Institute is a research institute based in Germany. The institute is driven by its staff and their ideas, combining professional experience, scientific expertise, and motivation to conduct non-mainstream medical research. CRI's approach is fresh and innovative, strictly adhering to international standards. The institute is located in Bavaria, overlooking Munich and the mountains. CRI's staff members are creative and innovative in their approach, delivering high-level publications and adhering to international standards.

About ARCHIMED:

ARCHIMED is a leading investment firm focused exclusively on the healthcare industry. With offices in Europe, North America, and Asia, ARCHIMED provides strategic and financial support to healthcare businesses. The firm's areas of focus include biopharma products, consumer health, healthcare IT, in vitro diagnostics, life science tools and biologic services, MedTech, and pharma services. ARCHIMED helps its partners internationalize, acquire, innovate, and expand their products and services. With €8 billion under management, ARCHIMED is committed to being an impact investor, supporting positive change in the healthcare industry.

In conclusion, NAMSA's acquisition of CRI is a significant move that will expand its clinical research capabilities and geographic reach across Europe. This strategic partnership will enable NAMSA to better serve its clients and continue its mission of improving healthcare outcomes for patients worldwide.